Pfizer lung cancer drug misses survival goal in Phase 3 trial

June 22, 2026 4:30 PM

Pfizer Inc. (NYSE: PFE) announced topline results from its Phase 3 SigVie-002 study evaluating sigvotatug vedotin, an investigational integrin beta-6 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found